

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER				PATENT APPLICATION		
Serial No. 09/389,782	Filing Date September 3, 1999	Examiner Not Assigned	Attorney's Docket No: A-604			
In Re Application of Dunstan et al.						
For OPG Fusion Protein Compositions and Methods						
TO THE ASSISTANT COMMISSIONER FOR PATENTS:						
<input checked="" type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):						
<input checked="" type="checkbox"/> One month of original due date (\$110.00) <input type="checkbox"/> Two months of original due date (\$380.00) <input type="checkbox"/> Three months of original due date (\$870.00) <input type="checkbox"/> Four months of original due date (\$1,360.00) <input type="checkbox"/> Five months of original due date (\$1,850.00)						
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested:						
<input checked="" type="checkbox"/> is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuing prosecution application having an express abandonment conditioned on the granting of a filing date to the continuing application.						
<input type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required. <input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
CLAIMS AS AMENDED						
(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for	(5) No. of extra claims present	(6) Rate	(7) Additional Fee
Total Claims	*	Minus	** =		x \$18	=
Indep. Claims	*	Minus	*** =		x \$78	=
<input type="checkbox"/> First Appearance of a multiple dependent claim					+\$260	=
Total Additional Fee for this Amendment						

*If the entry in column 2 is less than the entry in column 4, write "0" in column 5.
**If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
***If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The following other fees are incurred by the accompanying papers.
 Other: _____

Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$110.00. A duplicate copy of this petition is attached.

If an additional extension of time is required, please consider this a request therefore.
 The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.

Please Send Future Correspondence To:
US Patent Operations/RBW
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.:34,458
Phone: (805) 447-2425
Date: NOVEMBER 6, 1999

09389782
010519
00000025
110.00 CH
11/18/1999 ZABALA 00000025
01 FC:115

RECEIVED
NOV 22 1999

TECH CENTER 1600/2900


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

11/10/99
Date

Allen J. Sorenson
Signature

G-AU 7042
B #5
Box Seg
NL
1-5-00
#4



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
09/369,782	09/03/99	DUNSTAN	A-6114

09/369,782 09/03/99 DUNSTAN
02270922

BEST AVAILABLE COPY

U S PATENT OPERATIONS R&W
DEPT 430 M/S 27 4 A
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS CA 91320-1799

NOT ASSIGNED

1643

DATE MAILED:

09/17/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. OTHER: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123.
 For CRF submission help, call (703) 308-4212.
 For PatentIn software help, call (703) 308-6856.


Custom Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE